Azithromycin mass drug administration to reduce childhood mortality in humanitarian crises.

Authors

Gregory Barnsley, Matthew Coldiron, Neal Russell, Aula Abbara, Douglas James Noble, Stefan Flasche, Kevin van Zandvoort, Bhargavi Rao

Published in

PLOS global public health. Volume 6. Issue 7. Pages e0006684. Epub Jul 10, 2026.

Abstract

Azithromycin mass drug administration (MDA) can reduce under-5 mortality in stable but high-mortality settings, yet its potential in humanitarian crises remains undefined. This review proposes that azithromycin MDA could support existing humanitarian interventions and help address mortality from respiratory and gastrointestinal infections in displaced populations. Mortality rates in crises frequently exceed WHO recommended thresholds for initiating MDA. Operationally, the MDA is feasible, low-cost, and synergises with existing relief efforts like vaccination. While antimicrobial resistance (AMR) is a serious concern, the proposed use, likely a single round or short-term intervention during acute emergencies, may mitigate long-term resistance selection compared to routine biannual dosing. The potential to rapidly reduce excess mortality may outweigh the AMR risks. Azithromycin MDA represents a promising new tool for humanitarian health, though evidence-based protocols and resistance monitoring strategies must be developed through further research.

PMID:
42430338
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.